CSL

CSL Accounts Payable

$408.40MQuarterly · USD

Period ending:

CSL FY Accounts PayableUSD
CSL FY Accounts Payable1985-12-31: $0.001986-12-31: $0.001987-12-31: $0.001988-12-31: $0.001989-12-31: $31.90M1990-12-31: $31.00M1991-12-31: $24.40M1992-12-31: $19.20M1993-12-31: $28.70M1994-12-31: $34.10M1995-12-31: $45.20M1996-12-31: $74.30M1997-12-31: $75.90M1998-12-31: $101.90M1999-12-31: $106.30M2000-12-31: $108.48M2001-12-31: $137.10M2002-12-31: $148.61M2003-12-31: $144.61M2004-12-31: $167.95M2005-12-31: $127.56M2006-12-31: $142.41M2007-12-31: $132.50M2008-12-31: $128.70M2009-12-31: $132.70M2010-12-31: $195.40M2011-12-31: $260.80M2012-12-31: $205.90M2013-12-31: $187.00M2014-12-31: $198.00M2015-12-31: $212.60M2016-12-31: $243.60M2017-12-31: $332.10M2018-12-31: $312.10M2019-12-31: $327.30M2020-12-31: $284.50M2021-12-31: $432.40M2022-12-31: $273.50M2023-12-31: $245.50M2024-12-31: $261.10M2025-12-31: $233.00M$432.40M$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

CSL accounts payable history

Amounts owed to suppliers. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Carlisle Companies Incorporated Common Stock Accounts Payable — Annual fiscal periods (USD)
Period endingAccounts Payable (USD)
233,000,000
261,100,000
245,500,000
273,500,000
432,400,000
284,500,000
327,300,000
312,100,000
332,100,000
243,600,000
212,600,000
198,000,000
187,000,000
205,900,000
260,800,000
195,400,000
132,700,000
128,700,000
132,500,000
142,405,000
127,558,000
167,950,000
144,605,000
148,608,000
137,098,000
108,484,000
106,300,000
101,900,000
75,900,000
74,300,000
45,200,000
34,100,000
28,700,000
19,200,000
24,400,000
31,000,000
31,900,000
0
0
0
0

Compare accounts payable

All CSL financial metrics · CSL stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.